Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 189

1.

Identification of biomarkers of immune checkpoint blockade efficacy in recurrent or refractory solid tumor malignancies.

Yang RK, Qing Y, Jelloul FZ, Routbort MJ, Wang P, Shaw K, Zhang J, Lee J, Medeiros LJ, Kopetz S, Tetzlaff MT, Broaddus RR.

Oncotarget. 2020 Feb 11;11(6):600-618. doi: 10.18632/oncotarget.27466. eCollection 2020 Feb 11.

2.

Association of T and N Categories of the American Joint Commission on Cancer, 8th Edition, With Metastasis and Survival in Patients With Orbital Sarcoma.

Sa HS, Rubin ML, Ning J, Li W, Tetzlaff MT, McGovern SL, Paulino AC, Herzog CE, Gill JB, Esmaeli B.

JAMA Ophthalmol. 2020 Feb 27. doi: 10.1001/jamaophthalmol.2020.0039. [Epub ahead of print]

PMID:
32105303
3.

BAP1-inactivated melanocytic tumor with preserved BAP1 expression? Morphology to the rescue!

Duncan LM, Tetzlaff MT.

J Cutan Pathol. 2020 Feb 24. doi: 10.1111/cup.13671. [Epub ahead of print]

PMID:
32096236
4.

Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma.

Haydu LE, Lo SN, McQuade JL, Amaria RN, Wargo J, Ross MI, Cormier JN, Lucci A, Lee JE, Ferguson SD, Saw RPM, Spillane AJ, Shannon KF, Stretch JR, Hwu P, Patel SP, Diab A, Wong MKK, Glitza Oliva IC, Tawbi H, Carlino MS, Menzies AM, Long GV, Lazar AJ, Tetzlaff MT, Scolyer RA, Gershenwald JE, Thompson JF, Davies MA.

J Clin Oncol. 2020 Jan 28:JCO1901508. doi: 10.1200/JCO.19.01508. [Epub ahead of print]

PMID:
31990608
5.

B cells and tertiary lymphoid structures promote immunotherapy response.

Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, Yizhak K, Sade-Feldman M, Blando J, Han G, Gopalakrishnan V, Xi Y, Zhao H, Amaria RN, Tawbi HA, Cogdill AP, Liu W, LeBleu VS, Kugeratski FG, Patel S, Davies MA, Hwu P, Lee JE, Gershenwald JE, Lucci A, Arora R, Woodman S, Keung EZ, Gaudreau PO, Reuben A, Spencer CN, Burton EM, Haydu LE, Lazar AJ, Zapassodi R, Hudgens CW, Ledesma DA, Ong S, Bailey M, Warren S, Rao D, Krijgsman O, Rozeman EA, Peeper D, Blank CU, Schumacher TN, Butterfield LH, Zelazowska MA, McBride KM, Kalluri R, Allison J, Petitprez F, Fridman WH, Sautès-Fridman C, Hacohen N, Rezvani K, Sharma P, Tetzlaff MT, Wang L, Wargo JA.

Nature. 2020 Jan;577(7791):549-555. doi: 10.1038/s41586-019-1922-8. Epub 2020 Jan 15.

PMID:
31942075
6.

Whole-exome sequencing for ocular adnexal sebaceous carcinoma suggests PCDH15 as a novel mutation associated with metastasis.

Xu S, Moss TJ, Laura Rubin M, Ning J, Eterovic K, Yu H, Jia R, Fan X, Tetzlaff MT, Esmaeli B.

Mod Pathol. 2020 Jan 14. doi: 10.1038/s41379-020-0454-y. [Epub ahead of print]

PMID:
31937901
7.

Lichen planus related to transforming growth factor beta inhibitor in a patient with metastatic chondrosarcoma: a case report.

Farah M, Nelson KC, Tetzlaff MT, Nagarajan P, Torres-Cabala CA, Prieto VG, Curry JL, Aung PP.

J Cutan Pathol. 2020 Jan 12. doi: 10.1111/cup.13645. [Epub ahead of print]

PMID:
31930527
8.

Aberrant DNA Methylation Predicts Melanoma-Specific Survival in Patients with Acral Melanoma.

Pradhan D, Jour G, Milton D, Vasudevaraja V, Tetzlaff MT, Nagarajan P, Curry JL, Ivan D, Long L, Ding Y, Ezhilarasan R, Sulman EP, Diab A, Hwu WJ, Prieto VG, Torres-Cabala CA, Aung PP.

Cancers (Basel). 2019 Dec 16;11(12). pii: E2031. doi: 10.3390/cancers11122031.

9.

Variable Expression of MSH6 in Endometrial Carcinomas With Intact Mismatch Repair and With MLH1 Loss Due to MLH1 Methylation.

Tandon N, Hudgens C, Fellman B, Tetzlaff MT, Broaddus RR.

Int J Gynecol Pathol. 2019 Dec 18. doi: 10.1097/PGP.0000000000000655. [Epub ahead of print]

PMID:
31855955
10.

Immunohistochemical and Molecular Features of Melanomas Exhibiting Intratumor and Intertumor Histomorphologic Heterogeneity.

Mejbel HA, Arudra SKC, Pradhan D, Torres-Cabala CA, Nagarajan P, Tetzlaff MT, Curry JL, Ivan D, Duose DY, Luthra R, Prieto VG, Ballester LY, Aung PP.

Cancers (Basel). 2019 Nov 2;11(11). pii: E1714. doi: 10.3390/cancers11111714.

11.
12.

Unusual cutaneous metastatic carcinoma.

Ruiz SJ, Al Salihi S, Prieto VG, Nagarajan P, Tetzlaff MT, Curry JL, Ivan D, Torres-Cabala CA, Aung PP.

Ann Diagn Pathol. 2019 Dec;43:151399. doi: 10.1016/j.anndiagpath.2019.08.003. Epub 2019 Aug 12. Review.

PMID:
31675677
13.

The evolving landscape of HPV-related neoplasia in the head and neck.

Devins KM, Tetzlaff MT, Baloch Z, LiVolsi VA.

Hum Pathol. 2019 Dec;94:29-39. doi: 10.1016/j.humpath.2019.09.001. Epub 2019 Oct 22.

PMID:
31654690
14.

Correlation of Tumor Burden in Sentinel Lymph Nodes with Tumor Burden in Nonsentinel Lymph Nodes and Survival in Cutaneous Melanoma.

Namikawa K, Aung PP, Milton DR, Tetzlaff MT, Torres-Cabala CA, Curry JL, Nagarajan P, Ivan D, Ross M, Gershenwald JE, Prieto VG.

Clin Cancer Res. 2019 Dec 15;25(24):7585-7593. doi: 10.1158/1078-0432.CCR-19-1194. Epub 2019 Sep 30.

PMID:
31570567
15.

Multiplex Immunofluorescence Assays.

Francisco-Cruz A, Parra ER, Tetzlaff MT, Wistuba II.

Methods Mol Biol. 2020;2055:467-495. doi: 10.1007/978-1-4939-9773-2_22.

PMID:
31502166
16.

Measurement of Tumor Thickness in Cutaneous Squamous Cell Carcinomas: Do the Different Methods Provide Better Prognostic Data?

Yildiz P, Aung PP, Milton DR, Hruska C, Ivan D, Nagarajan P, Tetzlaff MT, Curry JL, Torres-Cabala C, Prieto VG.

Am J Dermatopathol. 2019 Aug 22. doi: 10.1097/DAD.0000000000001511. [Epub ahead of print]

PMID:
31464719
17.

PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer.

Liu B, Li L, Yang G, Geng C, Luo Y, Wu W, Manyam GC, Korentzelos D, Park S, Tang Z, Wu C, Dong Z, Sigouros M, Sboner A, Beltran H, Chen Y, Corn PG, Tetzlaff MT, Troncoso P, Broom B, Thompson TC.

Clin Cancer Res. 2019 Nov 15;25(22):6839-6851. doi: 10.1158/1078-0432.CCR-19-0317. Epub 2019 Aug 22.

PMID:
31439587
18.

A Novel Mitochondrial Inhibitor Blocks MAPK Pathway and Overcomes MAPK Inhibitor Resistance in Melanoma.

Vashisht Gopal YN, Gammon S, Prasad R, Knighton B, Pisaneschi F, Roszik J, Feng N, Johnson S, Pramanik S, Sudderth J, Sui D, Hudgens C, Fischer GM, Deng W, Reuben A, Peng W, Wang J, McQuade JL, Tetzlaff MT, Di Francesco ME, Marszalek J, Piwnica-Worms D, DeBerardinis RJ, Davies MA.

Clin Cancer Res. 2019 Nov 1;25(21):6429-6442. doi: 10.1158/1078-0432.CCR-19-0836. Epub 2019 Aug 22.

PMID:
31439581
19.

Greater Tumor Thickness, Ulceration, and Positive Sentinel Lymph Node Are Associated With Worse Prognosis in Patients With Conjunctival Melanoma: Implications for Future AJCC Classifications.

Esmaeli B, Rubin ML, Xu S, Goepfert RP, Curry JL, Prieto VG, Ning J, Tetzlaff MT.

Am J Surg Pathol. 2019 Dec;43(12):1701-1710. doi: 10.1097/PAS.0000000000001344.

PMID:
31425167
20.

Prognostic model for patient survival in primary anorectal mucosal melanoma: stage at presentation determines relevance of histopathologic features.

Nagarajan P, Piao J, Ning J, Noordenbos LE, Curry JL, Torres-Cabala CA, Diwan AH, Ivan D, Aung PP, Ross MI, Royal RE, Wargo JA, Wang WL, Samdani R, Lazar AJ, Rashid A, Davies MA, Prieto VG, Gershenwald JE, Tetzlaff MT.

Mod Pathol. 2020 Mar;33(3):496-513. doi: 10.1038/s41379-019-0340-7. Epub 2019 Aug 5.

PMID:
31383963
21.

Cutaneous neoplasms composed of melanoma and carcinoma: A rare but important diagnostic pitfall and review of the literature.

Mejbel HA, Nelson KC, Pradhan D, Ivan D, Zaleski M, Nagarajan P, Tetzlaff MT, Curry JL, Torres-Cabala CA, Prieto VG, Aung PP.

J Cutan Pathol. 2020 Jan;47(1):36-46. doi: 10.1111/cup.13551. Epub 2019 Aug 11.

PMID:
31361351
22.

Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium.

Amaria RN, Menzies AM, Burton EM, Scolyer RA, Tetzlaff MT, Antdbacka R, Ariyan C, Bassett R, Carter B, Daud A, Faries M, Fecher LA, Flaherty KT, Gershenwald JE, Hamid O, Hong A, Kirkwood JM, Lo S, Margolin K, Messina J, Postow MA, Rizos H, Ross MI, Rozeman EA, Saw RPM, Sondak V, Sullivan RJ, Taube JM, Thompson JF, van de Wiel BA, Eggermont AM, Davies MA; International Neoadjuvant Melanoma Consortium members, Ascierto PA, Spillane AJ, van Akkooi ACJ, Wargo JA, Blank CU, Tawbi HA, Long GV.

Lancet Oncol. 2019 Jul;20(7):e378-e389. doi: 10.1016/S1470-2045(19)30332-8. Review.

PMID:
31267972
23.

Lichenoid dermatitis from immune checkpoint inhibitor therapy: An immune-related adverse event with mycosis-fungoides-like morphologic and molecular features.

Tetzlaff MT, Tang S, Duke T, Grabell DA, Cabanillas ME, Zuo Z, Yao JC, Nagarajan P, Aung PP, Torres-Cabala CA, Duvic M, Prieto VG, Huen A, Curry JL.

J Cutan Pathol. 2019 Nov;46(11):872-877. doi: 10.1111/cup.13536. Epub 2019 Jul 15.

PMID:
31254410
24.

Expression of PD-1 and PD-L1 in Extramammary Paget Disease: Implications for Immune-Targeted Therapy.

Mauzo SH, Tetzlaff MT, Milton DR, Siroy AE, Nagarajan P, Torres-Cabala CA, Ivan D, Curry JL, Hudgens CW, Wargo JA, Sahin AA, Pettaway CA, Prieto VG, Aung PP.

Cancers (Basel). 2019 May 29;11(6). pii: E754. doi: 10.3390/cancers11060754.

25.

PD-L1/PD1 Expression, Composition of Tumor-Associated Immune Infiltrate, and HPV Status in Conjunctival Squamous Cell Carcinoma.

Nagarajan P, El-Hadad C, Gruschkus SK, Ning J, Hudgens CW, Sagiv O, Gross N, Tetzlaff MT, Esmaeli B.

Invest Ophthalmol Vis Sci. 2019 May 1;60(6):2388-2398. doi: 10.1167/iovs.19-26894.

26.

Prognostic Significance of "Nonsolid" Microscopic Metastasis in Merkel Cell Carcinoma Sentinel Lymph Nodes.

Erstine EM, Tetzlaff MT, Jia X, Aung PP, Prieto VG, Funchain P, Gastman BR, Billings SD, Ko JS.

Am J Surg Pathol. 2019 Jul;43(7):907-919. doi: 10.1097/PAS.0000000000001277.

PMID:
31094923
27.

Poor Response to Neoadjuvant Chemotherapy Correlates with Mast Cell Infiltration in Inflammatory Breast Cancer.

Reddy SM, Reuben A, Barua S, Jiang H, Zhang S, Wang L, Gopalakrishnan V, Hudgens CW, Tetzlaff MT, Reuben JM, Tsujikawa T, Coussens LM, Wani K, He Y, Villareal L, Wood A, Rao A, Woodward WA, Ueno NT, Krishnamurthy S, Wargo JA, Mittendorf EA.

Cancer Immunol Res. 2019 Jun;7(6):1025-1035. doi: 10.1158/2326-6066.CIR-18-0619. Epub 2019 May 1.

PMID:
31043414
28.

IL17A Blockade Successfully Treated Psoriasiform Dermatologic Toxicity from Immunotherapy.

Johnson D, Patel AB, Uemura MI, Trinh VA, Jackson N, Zobniw CM, Tetzlaff MT, Hwu P, Curry JL, Diab A.

Cancer Immunol Res. 2019 Jun;7(6):860-865. doi: 10.1158/2326-6066.CIR-18-0682. Epub 2019 Apr 17.

PMID:
30996018
29.

A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors.

Bentebibel SE, Hurwitz ME, Bernatchez C, Haymaker C, Hudgens CW, Kluger HM, Tetzlaff MT, Tagliaferri MA, Zalevsky J, Hoch U, Fanton C, Aung S, Hwu P, Curti BD, Tannir NM, Sznol M, Diab A.

Cancer Discov. 2019 Jun;9(6):711-721. doi: 10.1158/2159-8290.CD-18-1495. Epub 2019 Apr 15.

PMID:
30988166
30.

Gene expression profiling of lichenoid dermatitis immune-related adverse event from immune checkpoint inhibitors reveals increased CD14+ and CD16+ monocytes driving an innate immune response.

Curry JL, Reuben A, Szczepaniak-Sloane R, Ning J, Milton DR, Lee CH, Hudgens C, George S, Torres-Cabala C, Johnson D, Subramanya S, Wargo JA, Mudaliar K, Wistuba II, Prieto VG, Diab A, Tetzlaff MT.

J Cutan Pathol. 2019 Sep;46(9):627-636. doi: 10.1111/cup.13454. Epub 2019 Apr 11.

PMID:
30883858
31.

Validation Study of the AJCC Cancer Staging Manual, Eighth Edition, Staging System for Eyelid and Periocular Squamous Cell Carcinoma.

Xu S, Sagiv O, Rubin ML, Sa HS, Tetzlaff MT, Nagarajan P, Ning J, Esmaeli B.

JAMA Ophthalmol. 2019 May 1;137(5):537-542. doi: 10.1001/jamaophthalmol.2019.0238. Erratum in: JAMA Ophthalmol. 2019 May 1;137(5):587.

32.

Predictors of Local Recurrence for Eyelid Sebaceous Carcinoma: Questionable Value of Routine Conjunctival Map Biopsies for Detection of Pagetoid Spread.

Sa HS, Tetzlaff MT, Esmaeli B.

Ophthalmic Plast Reconstr Surg. 2019 Sep/Oct;35(5):419-425. doi: 10.1097/IOP.0000000000001343.

PMID:
30865067
33.

Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD).

Ferguson SD, Bindal S, Bassett RL Jr, Haydu LE, McCutcheon IE, Heimberger AB, Li J, O'Brien BJ, Guha-Thakurta N, Tetzlaff MT, Tawbi H, Davies MA, Glitza IC.

J Neurooncol. 2019 May;142(3):499-509. doi: 10.1007/s11060-019-03121-2. Epub 2019 Mar 7.

PMID:
30847840
34.

B7-H3 Expression in Merkel Cell Carcinoma-Associated Endothelial Cells Correlates with Locally Aggressive Primary Tumor Features and Increased Vascular Density.

Aung PP, Parra ER, Barua S, Sui D, Ning J, Mino B, Ledesma DA, Curry JL, Nagarajan P, Torres-Cabala CA, Efstathiou E, Hoang AG, Wong MK, Wargo JA, Lazar AJ, Rao A, Prieto VG, Wistuba I, Tetzlaff MT.

Clin Cancer Res. 2019 Jun 1;25(11):3455-3467. doi: 10.1158/1078-0432.CCR-18-2355. Epub 2019 Feb 26.

PMID:
30808776
35.

Melanoma With Loss of BAP1 Expression in Patients With No Family History of BAP1-Associated Cancer Susceptibility Syndrome: A Case Series.

Aung PP, Nagarajan P, Tetzlaff MT, Curry JL, Tang G, Abdullaev Z, Pack SD, Ivan D, Prieto VG, Torres-Cabala CA.

Am J Dermatopathol. 2019 Mar;41(3):167-179. doi: 10.1097/DAD.0000000000001217.

PMID:
30801340
36.

Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases.

Fischer GM, Jalali A, Kircher DA, Lee WC, McQuade JL, Haydu LE, Joon AY, Reuben A, de Macedo MP, Carapeto FCL, Yang C, Srivastava A, Ambati CR, Sreekumar A, Hudgens CW, Knighton B, Deng W, Ferguson SD, Tawbi HA, Glitza IC, Gershenwald JE, Vashisht Gopal YN, Hwu P, Huse JT, Wargo JA, Futreal PA, Putluri N, Lazar AJ, DeBerardinis RJ, Marszalek JR, Zhang J, Holmen SL, Tetzlaff MT, Davies MA.

Cancer Discov. 2019 May;9(5):628-645. doi: 10.1158/2159-8290.CD-18-1489. Epub 2019 Feb 20.

37.

Author Correction: Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis.

Wang Y, Wiesnoski DH, Helmink BA, Gopalakrishnan V, Choi K, DuPont HL, Jiang ZD, Abu-Sbeih H, Sanchez CA, Chang CC, Parra ER, Francisco-Cruz A, Raju GS, Stroehlein JR, Campbell MT, Gao J, Subudhi SK, Maru DM, Blando JM, Lazar AJ, Allison JP, Sharma P, Tetzlaff MT, Wargo JA, Jenq RR.

Nat Med. 2019 Jan;25(1):188. doi: 10.1038/s41591-018-0305-2.

PMID:
30479380
38.

Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis.

Wang Y, Wiesnoski DH, Helmink BA, Gopalakrishnan V, Choi K, DuPont HL, Jiang ZD, Abu-Sbeih H, Sanchez CA, Chang CC, Parra ER, Francisco-Cruz A, Raju GS, Stroehlein JR, Campbell MT, Gao J, Subudhi SK, Maru DM, Blando JM, Lazar AJ, Allison JP, Sharma P, Tetzlaff MT, Wargo JA, Jenq RR.

Nat Med. 2018 Dec;24(12):1804-1808. doi: 10.1038/s41591-018-0238-9. Epub 2018 Nov 12. Erratum in: Nat Med. 2018 Nov 27;:.

39.

Distinct Biological Types of Ocular Adnexal Sebaceous Carcinoma: HPV-Driven and Virus-Negative Tumors Arise through Nonoverlapping Molecular-Genetic Alterations.

Tetzlaff MT, Curry JL, Ning J, Sagiv O, Kandl TL, Peng B, Bell D, Routbort M, Hudgens CW, Ivan D, Kim TB, Chen K, Eterovic AK, Shaw K, Prieto VG, Yemelyanova A, Esmaeli B.

Clin Cancer Res. 2019 Feb 15;25(4):1280-1290. doi: 10.1158/1078-0432.CCR-18-1688. Epub 2018 Nov 12.

40.

Angiotropism in recurrent cutaneous squamous cell carcinoma: Implications for regional tumor recurrence and extravascular migratory spread.

Fedda F, Migden MR, Curry JL, Torres-Cabala CA, Tetzlaff MT, Aung PP, Prieto VG, Ivan D, Myers JN, Nagarajan P.

J Cutan Pathol. 2019 Feb;46(2):152-158. doi: 10.1111/cup.13388. Epub 2018 Dec 11.

PMID:
30414196
41.

Pathological Features and Clinical Course in Patients With Recurrent or Malignant Orbital Solitary Fibrous Tumor/Hemangiopericytoma.

Sagiv O, Bell D, Guo Y, Su S, Wester ST, Jiang K, Yin VT, Shinder R, Hayek B, Kim HJ, Tetzlaff MT, Esmaeli B.

Ophthalmic Plast Reconstr Surg. 2019 Mar/Apr;35(2):148-154. doi: 10.1097/IOP.0000000000001189.

PMID:
30371551
42.

Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.

Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA.

Nat Med. 2018 Dec;24(12):1942. doi: 10.1038/s41591-018-0252-y.

PMID:
30361511
43.

Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.

Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA.

Nat Med. 2018 Dec;24(12):1941. doi: 10.1038/s41591-018-0251-z.

PMID:
30361510
44.

Melanoma coexisting with solar elastosis: a potential pitfall in the differential diagnosis between nevus and melanoma.

Konopinski JC, Danialan R, Torres-Cabala CA, Tetzlaff MT, Nagarajan P, Curry JL, Ivan D, Prieto VG, Aung PP.

Hum Pathol. 2019 Feb;84:270-274. doi: 10.1016/j.humpath.2018.10.010. Epub 2018 Oct 22.

PMID:
30359637
45.

DNA Sequencing of Small Bowel Adenocarcinomas Identifies Targetable Recurrent Mutations in the ERBB2 Signaling Pathway.

Adam L, San Lucas FA, Fowler R, Yu Y, Wu W, Liu Y, Wang H, Menter D, Tetzlaff MT, Ensor J Jr, Manyam G, Arold ST, Huff C, Kopetz S, Scheet P, Overman MJ.

Clin Cancer Res. 2019 Jan 15;25(2):641-651. doi: 10.1158/1078-0432.CCR-18-1480. Epub 2018 Oct 23.

46.

Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.

Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA.

Nat Med. 2018 Nov;24(11):1649-1654. doi: 10.1038/s41591-018-0197-1. Epub 2018 Oct 8. Erratum in: Nat Med. 2018 Oct 25;:. Nat Med. 2018 Oct 25;:.

47.

Identification of a subset of microsatellite-stable endometrial carcinoma with high PD-L1 and CD8+ lymphocytes.

Crumley S, Kurnit K, Hudgens C, Fellman B, Tetzlaff MT, Broaddus R.

Mod Pathol. 2019 Mar;32(3):396-404. doi: 10.1038/s41379-018-0148-x. Epub 2018 Oct 5.

48.

Remodeling of the Collagen Matrix in Aging Skin Promotes Melanoma Metastasis and Affects Immune Cell Motility.

Kaur A, Ecker BL, Douglass SM, Kugel CH 3rd, Webster MR, Almeida FV, Somasundaram R, Hayden J, Ban E, Ahmadzadeh H, Franco-Barraza J, Shah N, Mellis IA, Keeney F, Kossenkov A, Tang HY, Yin X, Liu Q, Xu X, Fane M, Brafford P, Herlyn M, Speicher DW, Wargo JA, Tetzlaff MT, Haydu LE, Raj A, Shenoy V, Cukierman E, Weeraratna AT.

Cancer Discov. 2019 Jan;9(1):64-81. doi: 10.1158/2159-8290.CD-18-0193. Epub 2018 Oct 2.

49.

Post-radiation vascular lesions of the breast.

Ronen S, Ivan D, Torres-Cabala CA, Curry JL, Tetzlaff MT, Aung PP, Nagarajan P, Suster S, Prieto VG.

J Cutan Pathol. 2019 Jan;46(1):52-58. doi: 10.1111/cup.13363. Epub 2018 Nov 4. Review.

PMID:
30251277
50.

High expression of PD-1 and PD-L1 in ocular adnexal sebaceous carcinoma.

Kandl TJ, Sagiv O, Curry JL, Ning J, Ma J, Hudgens CW, Van Arnam J, Wargo JA, Esmaeli B, Tetzlaff MT.

Oncoimmunology. 2018 Jul 26;7(9):e1475874. doi: 10.1080/2162402X.2018.1475874. eCollection 2018.

Supplemental Content

Loading ...
Support Center